Epizyme, Inc. (NASDAQ:EPZM) – Stock analysts at Oppenheimer Holdings lifted their FY2017 EPS estimates for Epizyme in a note issued to investors on Wednesday. Oppenheimer Holdings analyst L. Cann now forecasts that the biopharmaceutical company will earn ($2.23) per share for the year, up from their prior estimate of ($2.54). Oppenheimer Holdings has a “Buy” rating and a $26.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Epizyme’s Q4 2017 earnings at ($0.57) EPS, Q1 2018 earnings at ($0.62) EPS, Q2 2018 earnings at ($0.75) EPS, Q3 2018 earnings at ($0.79) EPS, Q4 2018 earnings at ($0.23) EPS and FY2020 earnings at $1.61 EPS.

A number of other brokerages have also commented on EPZM. Leerink Swann restated an “outperform” rating and issued a $28.00 price target (down from $31.00) on shares of Epizyme in a report on Wednesday, August 9th. Royal Bank Of Canada restated a “buy” rating and issued a $20.00 price target on shares of Epizyme in a report on Friday, September 15th. BidaskClub upgraded Epizyme from a “strong sell” rating to a “sell” rating in a report on Saturday, August 5th. HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of Epizyme in a report on Thursday, November 2nd. Finally, Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. Epizyme has an average rating of “Buy” and an average target price of $22.67.

ILLEGAL ACTIVITY WARNING: This article was reported by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.watchlistnews.com/oppenheimer-holdings-weighs-in-on-epizyme-inc-s-fy2017-earnings-epzm/1684499.html.

Shares of Epizyme (NASDAQ EPZM) opened at $14.25 on Monday. Epizyme has a twelve month low of $8.90 and a twelve month high of $20.45.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.02.

In related news, Director David M. Mott bought 200,000 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The shares were acquired at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the acquisition, the director now owns 6,000 shares of the company’s stock, valued at approximately $91,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction dated Tuesday, October 24th. The stock was sold at an average price of $16.44, for a total value of $246,600.00. Following the sale, the insider now owns 23,123 shares in the company, valued at approximately $380,142.12. The disclosure for this sale can be found here. Insiders have sold 45,000 shares of company stock worth $733,950 in the last quarter. 25.20% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in EPZM. Legal & General Group Plc raised its stake in Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 795 shares during the period. UBS Asset Management Americas Inc. bought a new stake in Epizyme in the first quarter valued at approximately $175,000. BB&T Securities LLC bought a new stake in Epizyme in the second quarter valued at approximately $181,000. Trexquant Investment LP bought a new stake in Epizyme in the second quarter valued at approximately $184,000. Finally, SG Americas Securities LLC raised its stake in Epizyme by 83.3% in the second quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 6,072 shares during the period. Hedge funds and other institutional investors own 72.20% of the company’s stock.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Earnings History and Estimates for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.